The company's semi-annual performance has reached a new high.
Release time:
2020-08-14
Company's Semi-annual Performance Reached a New High
News 8# July 29 , the Group Company held the sixth meeting of the 10th Board of Directors and reviewed and approved the semi-annual report of Jianfeng Group 2018 . In the first half of this year, the company's overall net profit exceeded 3 .3 billion yuan, a record high. In the first half of
, the company focused on the general work policy of "grasping the trend, developing accurately, strengthening management and improving efficiency", actively explored new opportunities for development externally, continuously strengthened lean production and management improvement internally, continuously promoted the work of "three reductions and three improvements", and achieved the best semi-annual business performance in the past 18 years. During the reporting period, the company realized total operating income 303.35 yuan, up 15.09 year on year, net profit attributable to owners of the parent company 30,194.64 yuan, up 25.53 year on year. Earnings per share 0.88 yuan, return on net assets 10.79% . As of the end of 2018 6 , the company's total assets were 45.58 .6 billion yuan, up 9.15 year on year ; Net assets were 29.34 billion yuan, up 11.68 year on year. In the first half of the year, the company's cement sector has always adhered to the cost-leading strategy, continuously promoted management innovation, technological innovation, energy conservation and emission reduction, formulated competitive strategies according to the characteristics of their respective regional markets, actively explored the cement sales market, and achieved excellent semi-annual results. The net profits of Daye Peak and Yunnan Peak both exceeded 100 million yuan in the first half of the year, achieving net profits of
yuan and 11,259.12 yuan and yuan respectively. According to the company's overall development strategy, the pharmaceutical sector has conscientiously implemented various tasks, made new breakthroughs in project cooperation, and completed the holding of Shanghai Beika by way of capital increase and equity transfer, laying a good foundation for Jianfeng Pharmaceutical to establish an API base; While continuously expanding the scale of the industry, Jianfeng Pharmaceutical is also actively carrying out work such as applying for scientific and technological projects, speeding up product development, implementing drug bidding, and improving quality management. Jianfeng Health has done a good job in optimizing the structure of existing products, improving production processes, and reducing production costs. At the same time, it has increased the development of the terminal market and improved the construction of the new retail network platform, and achieved certain results. The peak international trade e-commerce logistics park project has achieved phased results, completed the construction of three standard logistics warehouses and handed over to the cooperative leasing party, for the peak international trade has brought new benefits growth point. In the second half of the year, the company will continue to focus on the annual business plan, adhere to the concept of high-quality development, carry out in-depth work of "three reductions and three improvements", further do a good job in internal control, prevent operational risks, further do a good job in safety and environmental protection, further develop and improve the complementary relatively diversified main business structure, and constantly enhance the company's core competitiveness. Maintain the healthy and stable development of the company. On the same day, the company also held the fourth meeting of the ninth board of supervisors and reviewed and approved the semi-annual report. (residual fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page